Logo

PharmaShots Weekly Snapshots (May 16 - 20, 2022)

Share this
PharmaShots Weekly Snapshots (May 16 - 20, 2022)

PharmaShots Weekly Snapshots (May 16 - 20, 2022)

Lipidor Reports Update on Patient Enrolment in P-III Clinical Study of AKP02 for the Treatment of Mild to Moderate Psoriasis

Published: May 20, 2022 | Tags: Lipidor, P-III, AKP02, Psoriasis

Mustang Bio Provides Updates of MB-107 in the P-I/II study for the Treatment of X-Linked Severe Combined Immunodeficiency

Published: May 20, 2022 | Tags: Mustang Bio, MB-107, P-I/II Study, X-Linked Severe Combined Immunodeficiency

Calliditas Receives CHMP Positive Opinion of Kinpeygo for the Treatment of Primary Immunoglobulin A Nephropathy

Published: May 20, 2022 | Tags: Calliditas, CHMP, Kinpeygo, Primary Immunoglobulin A Nephropathy

Abbott Presents Results of TriClip Device and Navitor TAVI System for Tricuspid Regurgitation & Aortic Stenosis at EuroPCR 2022

Published: May 20, 2022 | Tags: Abbott, TriClip Device, Navitor TAVI System, Tricuspid Regurgitation, Aortic Stenosis, EuroPCR, 2022

Zealand Reports Results of Dasiglucagon in P-III (17103) Trial for the Treatment of Congenital Hyperinsulinism in Pediatric Patients

Published: May 20, 2022 | Tags: Zealand, Dasiglucagon, P-III, 17103 Trial, Congenital Hyperinsulinism

Mirati Submits MAA to the EMA for Adagrasib (MRTX849) to Treat KRASG12C-Mutated Non-Small Cell Lung Cancer

Published: May 20, 2022 | Tags: Mirati, MAA, EMA, Adagrasib, KRASG12C-Mutated, Non-Small Cell Lung Cancer

Active Biotech’ Tasquinimod Receives the US FDA’s Orphan Drug Designation for the Treatment of Myelofibrosis

Published: May 19, 2022 | Tags: Active Biotech, Tasquinimod, US, FDA, Orphan Drug Designation, Myelofibrosis

Rocket Presents Results of RP-L201 in the P-II Trial for the Treatment of Severe Leukocyte Adhesion Deficiency-I at ASGCT 2022

Published: May 19, 2022 | Tags: Rocket, RP-L201, P-II Trial, Severe Leukocyte Adhesion Deficiency-I, ASGCT, 2022

IO Biotech Reports First Patient Dosing of IO102-IO103 + Keytruda (pembrolizumab) in the P-III (IOB-013 / KN-D18) Trial as 1L Treatment of Advanced Melanoma

Published: May 19, 2022 | Tags: IO Biotech, IO102-IO103, Keytruda, pembrolizumab, P-III, IOB-013, KN-D18 Trial, Melanoma

Axsome Reports Results of AXS-05 in the P-II (ASCEND) Study for the Treatment of Major Depressive Disorder

Published: May 19, 2022 | Tags: Axsome, AXS-05, P-II, ASCEND Study, Major Depressive Disorder

Evotec Collaborated with Almirall to Discover and Develop Novel Therapies for the Treatment of Skin Diseases

Published: May 19, 2022 | Tags: Evotec, Almirall, Novel Therapies, Skin Diseases, EVOiR&D Platform

Scilex Reports the Initiation of SP-103 in P-II Study for the Treatment of Acute Low Back Pain

Published: May 19, 2022 | Tags: Scilex, SP-103, P-II Study, Acute Low Back Pain

Teleflex’s MANTA Vascular Closure Device Receives Health Canada Approval for Large Bore Femoral Arterial Access Site Closure

Published: May 18, 2022 | Tags: Teleflex, MANTA Vascular Closure Device, Health Canada, Approval, Large Bore Femoral Arterial, Site Closure

4D Pharma Presents Results of MRx-4DP0004 in P-I/II Trial for the Treatment of Asthma at ATS 2022

Published: May 18, 2022 | Tags: 4D Pharma, MRx-4DP0004, P-I/II Trial, Asthma, ATS, 2022

Idera Stops P-II (INTRIM 1) Trial of Tilsotolimod (IMO-2125) Due to Positive Efficacy in Patients with Melanoma

Published: May 18, 2022 | Tags: Idera, P-II, INTRIM 1 Trial, Tilsotolimod, IMO-2125, Melanoma

Ultragenyx Entered into an Exclusive License Agreement with Abeona for ABO-102 (UX111) to Treat Sanfilippo Syndrome Type A

Published: May 18, 2022 | Tags: Ultragenyx, Abeona, ABO-102, UX111, Sanfilippo Syndrome Type A

Pfizer and BioNTech Report EUA Expansion for Booster Dose of COVID-19 Vaccine in Children Aged 5 Through 11 Years

Published: May 18, 2022 | Tags: Pfizer, BioNTech, EUA, Booster Dose, COVID-19, Vaccine

LifeArc Co-Founded Company RQ Bio Entered into a License Agreement with AstraZeneca to Develop Monoclonal Antibodies Against SARS-CoV-2

Published: May 18, 2022 | Tags: LifeArc, RQ Bio, AstraZeneca, Monoclonal Antibodies, SARS-CoV-2

MannKind Entered into an Agreement with Zealand to Acquire V-Go Insulin Delivery Device for the Treatment of Diabetes

Published: May 17, 2022 | Tags: MannKind, Zealand, Acquire, V-Go, Insulin Delivery Device, Diabetes

Evotec Collaborated with Sernova to Develop iPSC-Based Beta Cell Replacement Therapy for the Treatment of Diabetes

Published: May 17, 2022 | Tags: Evotec, Sernova, iPSC-Based, Beta Cell Replacement Therapy, Diabetes

Travere Therapeutics Reports US FDA Acceptance of NDA and Priority Review for Sparsentan to Treat IgA Nephropathy

Published: May 17, 2022 | Tags: Travere Therapeutics, US, FDA, NDA, Priority Review, Sparsentan, IgA Nephropathy

BMS Reports Results of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III (CheckMate -901) Trial as 1L Treatment for Unresectable or Metastatic Urothelial Carcinoma

Published: May 17, 2022 | Tags: BMS, Opdivo, nivolumab, Yervoy, ipilimumab, P-III, CheckMate -901 Trial, Urothelial Carcinoma

AbbVie Signs an Exclusive Worldwide License Option Agreement with Cugene for CUG252 to Treat Autoimmune Diseases

Published: May 17, 2022 | Tags: AbbVie, Option Agreement, Cugene, CUG252, Autoimmune Diseases

Proteros Expands 2021 Agreement with AstraZeneca to Develop Epigenetic Therapies for the Treatment of Cancer

Published: May 17, 2022 | Tags: Proteros, 2021, AstraZeneca, Epigenetic Therapies, Cancer

Emergent BioSolutions Entered into a Definitive Agreement with Chimerix to Acquire Tembexa (brincidofovir) Rights for Smallpox

Published: May 16, 2022 | Tags: Emergent BioSolutions, Chimerix, Acquire, Tembexa, brincidofovir, Smallpox

KemPharm Signs a Definitive Agreement with Orphazyme to Acquire Arimoclomol for the Treatment of Niemann-Pick Disease Type C

Published: May 16, 2022 | Tags: KemPharm, Orphazyme, Acquire, Arimoclomol, Niemann-Pick Disease Type C

Sanofi Presents Results of Sarclisa (isatuximab) in P-III (IKEMA) Trial for Relapsed Multiple Myeloma at COMy 2022

Published: May 16, 2022 | Tags: Sanofi, Sarclisa, isatuximab, P-III, IKEMA Trial, Relapsed Multiple Myeloma

Lilly's Mounjaro (tirzepatide) Receives the US FDA’s Approval for the Treatment of Adults with Type 2 Diabetes

Published: May 16, 2022 | Tags: Lilly, Mounjaro, tirzepatide, US, FDA, Approval, Type 2 Diabetes

AstraZeneca Reports Results of PT027 in a P-III (MANDALA) Trial as a Fixed-Dose Combination of Albuterol and Budesonide for Asthma

Published: May 16, 2022 | Tags: AstraZeneca, PT027, P-III, MANDALA Trial, Albuterol, Budesonide, Asthma

Urovant Presents Interim Results of URO-902 in P-IIa Study for the Treatment of Overactive Bladder at AUA 2022

Published: May 16, 2022 | Tags: Urovant Sciences, URO-902, P-IIa Study, Overactive Bladder, AUA, 2022

Related Post: PharmaShots Weekly Snapshots (May 09-13, 2022)


Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions